Home > Insider Trading > Filing (0000874015-23-000093)

Filing Details

Accession Number:: 0000874015-23-000093
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-02-07 17:36:55
Reporting Period:: 2023-02-03

Accepted Time:: 2023-02-07 17:36:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874015	Ionis Pharmaceuticals Inc	IONS	Pharmaceutical Preparations (2834)	330336973

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1537529	P Brett Monia	2855 Gazelle Court Carlsbad CA 92010	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-02-03	6,511	$0.00	127,374	No	4	A	Direct
Common Stock	Acquisiton	2023-02-03	17,210	$0.00	144,584	No	4	A	Direct
Common Stock	Acquisiton	2023-02-03	25,372	$0.00	169,956	No	4	A	Direct
Common Stock	Disposition	2023-02-06	24,651	$40.69	145,305	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	A	Direct
No	4	S	Direct

Footnotes

Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the final performance period of the grant to the reporting person reported on January 17, 2020. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 100% of target shares and a true-up of 72.24% of target shares pursuant to the alternative calculation. Since this PRSU award paid out less than 100% of target for tranche 1 and tranche 2 of such PRSU award, the alternative calculation applies, resulting in an additional payout of 1,146 shares under tranche 1 and 1,586 shares under tranche 2, yielding in the aggregate a total tranche 3 payout of 6,511 shares, or 172.24% of target
Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the second performance period of the grant to the reporting person reported on January 20, 2021. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 100% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.
Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the first performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.37 to $40.95 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.